| GDNF | giant cell line-derived neutrophilic factor |
|---|---|
| GIP | gastric inhibitory polypeptide; giant cell interstitial pneumonia; glucose-dependent insulinotropic ... |
| GMC | general medical clinic; general medical council; giant migratory contraction; grivet monkey cell |
| MCGC | metacerebral giant cell |
| MGCE | multifocal giant cell encephalitis |
| giant melanosome | A large spherical melanosome (1 to 6 u in diameter) formed in the cytoplasm of melanocytes in cafe-au-lait spots and other melanocytic disorders. Synonym: macromelanosome. (05 Mar 2000) |
|---|---|
| giant osteoid osteoma | A benign, painful, tumour of bone characterised by the formation of osteoid tissue, primitive bone and calcified tissue. It occurs frequently in the spine of young persons. (12 Dec 1998) |
| giant pigmented nevus | These large pigmented (often hairy) congenital nevi are important because of their increased risk (10 to 15%) of conversion into malignant melanoma. A biopsy can confirm if cells have turned malignant. Any change in a pre-existing nevus should prompt a physician evaluation. (27 Sep 1997) |
| giant urticaria | A vascular reaction involving the deep dermis or subcutaneous or submucal tissues, representing localised oedema caused by dilatation and increased permeability of the capillaries and characterised by development of giant wheals. (18 Nov 1997) |
| congenital giant pigmented nevus | These large pigmented (often hairy) congenital nevi are important because of their increased risk (10 to 15%) of conversion into malignant melanoma. A biopsy can confirm if cells have turned malignant. Any change in a pre-existing nevus should prompt a physician evaluation. (27 Sep 1997) |
| squid giant axon | <physiology> Large axons, up to 1mm in diameter, that innervate the mantle of the squid. Because of their large size, many of the pioneering investigations of the mechanisms underlying resting and action potentials in excitable cells were done on these fibres. (10 Mar 1998) |
| Langhans'-type giant cells | Multinucleated giant cell's seen in tuberculosis and other granulomas; the nuclei are arranged in an arciform manner at the periphery of the cell's. Synonym: Langhans'-type giant cells. Synonym: cytotrophoblastic cells. (05 Mar 2000) |
| T-cell-rich, B-cell lymphoma | <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component. See: adult T-cell lymphoma. (05 Mar 2000) |
| acute parenchymatous hepatitis | A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice. Synonym: acute parenchymatous hepatitis, Rokitansky's disease. (05 Mar 2000) |
| anicteric hepatitis | Hepatitis without jaundice. (05 Mar 2000) |
| anicteric virus hepatitis | A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis. (05 Mar 2000) |
| autoimmune hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
| vaccination, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| vaccination, infectious hepatitis | See Vaccination, hepatitis a. (12 Dec 1998) |